-
Generation of 3D Molecules in Pockets via Language Model
Authors:
Wei Feng,
Lvwei Wang,
Zaiyun Lin,
Yanhao Zhu,
Han Wang,
Jianqiang Dong,
Rong Bai,
Huting Wang,
Jielong Zhou,
Wei Peng,
Bo Huang,
Wenbiao Zhou
Abstract:
Generative models for molecules based on sequential line notation (e.g. SMILES) or graph representation have attracted an increasing interest in the field of structure-based drug design, but they struggle to capture important 3D spatial interactions and often produce undesirable molecular structures. To address these challenges, we introduce Lingo3DMol, a pocket-based 3D molecule generation method…
▽ More
Generative models for molecules based on sequential line notation (e.g. SMILES) or graph representation have attracted an increasing interest in the field of structure-based drug design, but they struggle to capture important 3D spatial interactions and often produce undesirable molecular structures. To address these challenges, we introduce Lingo3DMol, a pocket-based 3D molecule generation method that combines language models and geometric deep learning technology. A new molecular representation, fragment-based SMILES with local and global coordinates, was developed to assist the model in learning molecular topologies and atomic spatial positions. Additionally, we trained a separate noncovalent interaction predictor to provide essential binding pattern information for the generative model. Lingo3DMol can efficiently traverse drug-like chemical spaces, preventing the formation of unusual structures. The Directory of Useful Decoys-Enhanced (DUD-E) dataset was used for evaluation. Lingo3DMol outperformed state-of-the-art methods in terms of drug-likeness, synthetic accessibility, pocket binding mode, and molecule generation speed.
△ Less
Submitted 11 December, 2023; v1 submitted 17 May, 2023;
originally announced May 2023.
-
Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 2 -- Ex vivo imaging: added value and acquisition
Authors:
Kurt G Schilling,
Francesco Grussu,
Andrada Ianus,
Brian Hansen,
Amy FD Howard,
Rachel L C Barrett,
Manisha Aggarwal,
Stijn Michielse,
Fatima Nasrallah,
Warda Syeda,
Nian Wang,
Jelle Veraart,
Alard Roebroeck,
Andrew F Bagdasarian,
Cornelius Eichner,
Farshid Sepehrband,
Jan Zimmermann,
Lucas Soustelle,
Christien Bowman,
Benjamin C Tendler,
Andreea Hertanu,
Ben Jeurissen,
Lucio Frydman,
Yohan van de Looij,
David Hike
, et al. (32 additional authors not shown)
Abstract:
The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher signal-to-noise ratio and spatial resolution compared to in vivo studies, and enabling more advanced diffusion cont…
▽ More
The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher signal-to-noise ratio and spatial resolution compared to in vivo studies, and enabling more advanced diffusion contrasts. Another major advantage of ex vivo dMRI is the direct comparison with histological data as a methodological validation. However, there are a number of considerations that must be made when performing ex vivo experiments. The steps from tissue preparation, image acquisition and processing, and interpretation of results are complex, with decisions that not only differ dramatically from in vivo imaging of small animals, but ultimately affect what questions can be answered using the data. This work represents "Part 2" of a 3-part series of recommendations and considerations for preclinical dMRI. We describe best practices for dMRI of ex vivo tissue, with a focus on the value that ex vivo imaging adds to the field of dMRI and considerations in ex vivo image acquisition. We give general considerations and foundational knowledge that must be considered when designing experiments. We describe differences in specimens and models and discuss why some may be more or less appropriate for different studies. We then give guidelines for ex vivo protocols, including tissue fixation, sample preparation, and MR scanning. In each section, we attempt to provide guidelines and recommendations, but also highlight areas for which no guidelines exist (and why), and where future work should lie. An overarching goal herein is to enhance the rigor and reproducibility of ex vivo dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
△ Less
Submitted 24 October, 2024; v1 submitted 27 September, 2022;
originally announced September 2022.
-
Considerations and Recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 1 -- In vivo small-animal imaging
Authors:
Ileana O Jelescu,
Francesco Grussu,
Andrada Ianus,
Brian Hansen,
Rachel L C Barrett,
Manisha Aggarwal,
Stijn Michielse,
Fatima Nasrallah,
Warda Syeda,
Nian Wang,
Jelle Veraart,
Alard Roebroeck,
Andrew F Bagdasarian,
Cornelius Eichner,
Farshid Sepehrband,
Jan Zimmermann,
Lucas Soustelle,
Christien Bowman,
Benjamin C Tendler,
Andreea Hertanu,
Ben Jeurissen,
Marleen Verhoye,
Lucio Frydman,
Yohan van de Looij,
David Hike
, et al. (32 additional authors not shown)
Abstract:
Small-animal diffusion MRI (dMRI) has been used for methodological development and validation, characterizing the biological basis of diffusion phenomena, and comparative anatomy. The steps from animal setup and monitoring, to acquisition, analysis, and interpretation are complex, with many decisions that may ultimately affect what questions can be answered using the resultant data. This work aims…
▽ More
Small-animal diffusion MRI (dMRI) has been used for methodological development and validation, characterizing the biological basis of diffusion phenomena, and comparative anatomy. The steps from animal setup and monitoring, to acquisition, analysis, and interpretation are complex, with many decisions that may ultimately affect what questions can be answered using the resultant data. This work aims to present selected recommendations and guidelines from the diffusion community, on best practices for preclinical dMRI of in vivo animals. We describe the general considerations and foundational knowledge that must be considered when designing experiments. We briefly describe differences in animal species and disease models and discuss why some may be more or less appropriate for different studies. We then give guidelines for in vivo acquisition protocols, including decisions on hardware, animal preparation, and imaging sequences, followed by advice for data processing including pre-processing, model-fitting, and tractography. Finally, we provide an online resource which lists publicly available preclinical dMRI datasets and software packages, to promote responsible and reproducible research. In each section, we attempt to provide guides and recommendations, but also highlight areas for which no guidelines exist (and why), and where future work should focus. While we mainly cover the central nervous system (on which most preclinical dMRI studies are focused), we also provide, where possible and applicable, recommendations for other organs of interest. An overarching goal herein is to enhance the rigor and reproducibility of small animal dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
△ Less
Submitted 21 November, 2024; v1 submitted 26 September, 2022;
originally announced September 2022.
-
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection
Authors:
Allison Koenecke,
Michael Powell,
Ruoxuan Xiong,
Zhu Shen,
Nicole Fischer,
Sakibul Huq,
Adham M. Khalafallah,
Marco Trevisan,
Pär Sparen,
Juan J Carrero,
Akihiko Nishimura,
Brian Caffo,
Elizabeth A. Stuart,
Renyuan Bai,
Verena Staedtke,
David L. Thomas,
Nickolas Papadopoulos,
Kenneth W. Kinzler,
Bert Vogelstein,
Shibin Zhou,
Chetan Bettegowda,
Maximilian F. Konig,
Brett Mensh,
Joshua T. Vogelstein,
Susan Athey
Abstract:
In severe viral pneumonia, including Coronavirus disease 2019 (COVID-19), the viral replication phase is often followed by hyperinflammation, which can lead to acute respiratory distress syndrome, multi-organ failure, and death. We previously demonstrated that alpha-1 adrenergic receptor ($α_1$-AR) antagonists can prevent hyperinflammation and death in mice. Here, we conducted retrospective analys…
▽ More
In severe viral pneumonia, including Coronavirus disease 2019 (COVID-19), the viral replication phase is often followed by hyperinflammation, which can lead to acute respiratory distress syndrome, multi-organ failure, and death. We previously demonstrated that alpha-1 adrenergic receptor ($α_1$-AR) antagonists can prevent hyperinflammation and death in mice. Here, we conducted retrospective analyses in two cohorts of patients with acute respiratory distress (ARD, n=18,547) and three cohorts with pneumonia (n=400,907). Federated across two ARD cohorts, we find that patients exposed to $α_1$-AR antagonists, as compared to unexposed patients, had a 34% relative risk reduction for mechanical ventilation and death (OR=0.70, p=0.021). We replicated these methods on three pneumonia cohorts, all with similar effects on both outcomes. All results were robust to sensitivity analyses. These results highlight the urgent need for prospective trials testing whether prophylactic use of $α_1$-AR antagonists ameliorates lower respiratory tract infection-associated hyperinflammation and death, as observed in COVID-19.
△ Less
Submitted 2 August, 2021; v1 submitted 21 April, 2020;
originally announced April 2020.
